Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 2001.
Key Event: The financial statements have been restated to reflect the pooling of interests merger with Bindley Western Industries, Inc. completed on February 14, 2001. A three-for-two stock split was distributed on April 20, 2001, and all share data is retroactively adjusted.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Mar 31, 2001 |
3 Months Ended Mar 31, 2000 |
9 Months Ended Mar 31, 2001 |
9 Months Ended Mar 31, 2000 |
|---|---|---|---|---|
| Total Revenue | $12,580.1 | $9,611.5 | $35,546.6 | $27,814.8 |
| Operating Earnings | $349.9 | $354.9 | $1,060.1 | $922.1 |
| Net Earnings | $192.9 | $198.4 | $604.1 | $511.8 |
| Diluted EPS | $0.42 | $0.44 | $1.33 | $1.14 |
| Gross Margin % | 7.52% | 8.24% | 7.42% | 8.14% |
| Cash & Equivalents | $396.2 | $369.0 | $396.2 | $369.0 |
| Working Capital | $4,015.1 | $2,900.0 | $4,015.1 | $2,900.0 |
Note: Working Capital calculated as Total Current Assets ($10,365.6M) minus Total Current Liabilities ($6,350.5M) for Mar 31, 2001. Prior year working capital estimated from June 30, 2000 balance sheet ($8,446.4M - $5,546.7M).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31% for the quarter and 28% for the nine-month period compared to the prior year. This growth was driven by the Bindley merger, increased volume from existing customers, and price increases.
- Margin Compression: Consolidated gross margin as a percentage of operating revenue declined to 9.15% (quarter) and 9.28% (nine months) from 10.33% and 10.21% in the prior year. This was primarily due to a higher mix of lower-margin pharmaceutical distribution sales and the acquisition of Bergen Brunswig Medical Corporation (BBMC).
- Special Charges: Special charges increased significantly to $86.3 million for the quarter and $106.6 million for the nine months, compared to $10.7 million and $53.0 million in the prior year. These charges were largely merger-related (transaction costs, employee severance, and facility consolidation).
- Balance Sheet: Merchandise inventories rose to $6.1 billion from $4.7 billion, and trade receivables increased to $2.9 billion from $2.4 billion, reflecting business volume growth and the Bindley acquisition.
Guidance, Outlook, and Risks
- Future Costs: Management estimates it will incur approximately $160.5 million ($101.1 million net of tax) in additional merger-related and integration costs in future periods, primarily through fiscal 2003.
- Liquidity: The company maintains a $1.5 billion commercial paper program and a $1.5 billion unsecured bank credit facility. It recently issued $500 million of 6.75% Notes due 2011 to refinance Bindley debt and fund general corporate purposes.
- Legal Contingencies: The company faces approximately 600 lawsuits regarding natural rubber latex glove sensitization (inherited from the Allegiance acquisition). While the company believes a substantial portion of liability will be covered by insurance, it cannot currently estimate the potential loss.
- Market Risks: No material change in exposure to market risk was reported compared to the prior fiscal year.
Investor Verification Checklist
- Merger Integration Costs: Verify the timeline and actual spend against the estimated $160.5 million in future merger-related costs.
- Latex Litigation Exposure: Monitor developments in the 600 pending latex glove lawsuits and insurance coverage status.
- Margin Trends: Assess whether the shift toward lower-margin pharmaceutical distribution will continue to pressure gross margins or if vendor programs will offset this.
- Inventory Levels: Review the $1.5 billion increase in inventory to ensure it aligns with sales velocity and does not indicate obsolescence risks.
- Debt Structure: Confirm the impact of the new $500 million note issuance on future interest expense and debt service requirements.